GCG and type 2 diabetes mellitus: Liraglutide, glucagon-like peptide-1 (GLP-1) analogue, is a member of the newest class of T2D therapies currently available, which improve hyperglycemia through increasing insulin secretion and reducing glucagon secretion[3], slowing gastric emptying, delaying carbohydrate absorption, and increasing satiety, leading to reduced caloric intake[4].